Anzeige
Mehr »
Samstag, 07.06.2025 - Börsentäglich über 12.000 News
Starke Zahlen: EBITDA bei 9 Mio.?€ - Startet jetzt die Neubewertung?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3CQ56 | ISIN: US23954D1090 | Ticker-Symbol:
NASDAQ
06.06.25 | 21:59
7,170 US-Dollar
+3,17 % +0,220
1-Jahres-Chart
DAY ONE BIOPHARMACEUTICALS INC Chart 1 Jahr
5-Tage-Chart
DAY ONE BIOPHARMACEUTICALS INC 5-Tage-Chart

Aktuelle News zur DAY ONE BIOPHARMACEUTICALS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DiDay One Biopharmaceuticals, Inc. - 8-K, Current Report3
06.05.Day One Biopharmaceuticals, Inc.: Day One Reports First Quarter 2025 Financial Results and Corporate Progress237OJEMDA (tovorafenib) prescriptions grew 16% in Q1 2025 compared to Q4 2024 Achieved Q1 2025 OJEMDA (tovorafenib) net product revenue of $30.5 million Ended the first quarter with $473.0 million in...
► Artikel lesen
06.05.Day One Biopharmaceuticals, Inc. - 10-Q, Quarterly Report1
06.05.Day One Biopharmaceuticals, Inc. - 8-K, Current Report1
22.04.Day One Biopharmaceuticals, Inc.: Day One to Report First Quarter 2025 Financial Results Tuesday, May 6, 20256
03.04.H.C. Wainwright maintains Buy on Day One Biopharmaceuticals8
06.03.Day One Biopharmaceuticals, Inc. - 10-K/A, Annual Report1
DAY ONE BIOPHARMACEUTICALS Aktie jetzt für 0€ handeln
26.02.Day One Biopharmaceuticals stock target cut to $36 at H.C. Wainwright8
25.02.Day One Biopharmaceuticals GAAP EPS of -$1.02 misses by $0.29, revenue of $131.16M beats by $8.64M2
25.02.Day One Biopharmaceuticals, Inc. - 8-K, Current Report1
11.02.Day One Biopharmaceuticals, Inc.: Day One to Report Fourth Quarter and Full-Year 2024 Financial Results Tuesday, February 25, 20257
23.01.Why Is Andreas Halvorsen Bullish On Day One Biopharmaceuticals, Inc. (DAWN) Now?13
13.01.Day One Biopharmaceuticals, Inc. - 8-K, Current Report1
10.01.Day One Biopharmaceuticals, Inc. - S-8, Securities to be offered to employees in employee benefit plans1
30.10.24Day One Biopharmaceuticals, Inc.: Day One Reports Third Quarter 2024 Financial Results and Corporate Progress370Achieved $20.1 million in OJEMDATM (tovorafenib) net product revenue Ended the third quarter with $558.4 million in cash, cash equivalents and short-term investments Company to host conference call...
► Artikel lesen
30.07.24Day One Biopharmaceuticals, Inc.: Day One Reports Second Quarter 2024 Financial Results and Corporate Progress349Achieved $8.2 million in OJEMDATM (tovorafenib) net product revenues in initial 2 months of launch Expanded pipeline with DAY301, potential first-in-class Antibody Drug Conjugate (ADC) targeting...
► Artikel lesen
18.06.24Day One Biopharmaceuticals, Inc.: Day One Expands Pipeline with Potential First-in-Class Clinical-Stage Antibody Drug Conjugate (ADC) Targeting PTK7 in Solid Tumors for Adult and Pediatric Cancers378Day One receives exclusive license for development and commercialization of MTX-13 (DAY301), which received IND clearance by the FDA in April 2024 Targets PTK7, highly expressed in broad range of...
► Artikel lesen
12.06.24XOMA Corporation: XOMA Receives $8.1 Million Milestone Related to Day One Biopharmaceuticals' Sale of its Priority Review Voucher371EMERYVILLE, Calif., June 12, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today it has received an $8.1 million milestone payment from Viracta...
► Artikel lesen
18 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,31,32